Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles' Heel of Targeted Therapy.
PDB-4rwi: Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M), apo 手法: X-RAY DIFFRACTION / 解像度: 2.292 Å
PDB-4rwj: Crystal Structure of FGFR1 (C488A, C584S) in complex with AZD4547 (N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) 手法: X-RAY DIFFRACTION / 解像度: 2.489 Å
PDB-4rwk: Crystal structure of V561M FGFR1 gatekeeper mutation (C488A, C584S, V561M) in complex with N-{3-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R,5S)-3,5-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547) 手法: X-RAY DIFFRACTION / 解像度: 2.982 Å
PDB-4rwl: Crystal structure of FGFR1 (C488A, C584C) in complex with 6-(7-((1-aminocyclopropyl) methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide (E3810) 手法: X-RAY DIFFRACTION / 解像度: 2.193 Å